Why insurers aren’t cheering CMS’ Medicare Advantage increase

CMS announced an increase to Medicare Advantage rates, but the adjustment did little to quell uncertainty for Medicare Advantage insurers. Insurers reacted cautiously, leaving potential pressure on revenue and near-term guidance for the sector and maintaining downside sentiment among investors.

Analysis

Insurers face a classic two-speed margin shock: headline rate tweaks leave headline premiums largely intact while uncertainty about risk-adjustment rules, coding intensity audits, and pass-throughs to providers create 50–150bps of effective margin volatility across plans over the next 6–12 months. That range is large enough to force reserve re-optimizations, pull forward or delay APM (value-based care) contracting, and compress free cash flow in smaller MA-heavy books where medical loss ratio sensitivity is highest.

Second-order winners will be vertically integrated players that can arbitrage multiple seams (risk-adjustment coding, PBM spread, care management) — they both smooth realized margins and have capital to step into market-dislocated assets. Losers are concentrated MA pure-plays and recently acquired sub-scale books where capital costs and reserve refresh cycles will bite; those sellers create M&A optionality but only after regulatory clarity.

Short-dated catalysts: CMS technical memos, risk-score recalibration updates, and spring enrollment flows will move sentiment within days-weeks; multi-quarter catalysts include audits and the next rule-making window where durable changes to transfer formulas or coding allowances could arrive. Tail risks include Congressional intervention or major litigation that could reprice expected MA growth for years, while a faster-than-expected reversion of coding intensity (lower risk scores) would materially compress EBITDA for exposed plans.

Consensus is treating the announcement as a one-off headline; we see the market underpricing the optionality for large, integrated insurers to monetize counterparty stress (M&A, buybacks) if smaller players visibly reprice or de-risk. That asymmetry creates an idiosyncratic opportunity to be long scale/verticals and short concentrated MA risk on a 3–12 month basis, with well-defined event triggers to harvest dispersion.

Key Decisions for Investors

• Long UNH (6–12 months): increase exposure to largest vertically integrated MA operator via outright shares or buy-call spread (buy 6–12 month ITM calls funded by selling 1–2 strikes OTM). Rationale: scale in risk adjustment and Optum revenue diversification should outperform peers if CMS technical guidance stabilizes. Target +15–25% upside vs ~10% downside to adverse regulatory moves; hedge with small put position tied to MA pure-plays.
• Short HUM or CNC (3–9 months): initiate modest put-spread (buy 3–6 month 15% OTM puts, sell 10% OTM) to limit premium outlay. Rationale: higher MA concentration, greater reserve sensitivity, and limited scale to absorb coding/audit noise. Risk limited to premium; potential 2–4x payout if coding/risk-score revisions materialize.
• Pair trade (6–12 months): long ELV or UNH / short CNC — equal notional. Rationale: long insurers with diversified revenue/PBM/Optum-like assets vs short concentrated MA names to exploit differential ability to retain margins and buy assets. Expect spread compression in 3–9 months if weaker peers deleverage or sell books.
• Event hedge (days–weeks): buy short-dated straddles on headlines tied to CMS memos and enrollment windows (trades around expected guidance dates). Rationale: volatility spikes around technical clarifications; preserve upside from surprise clarifications while limiting directional exposure. Position size small relative to core book given time decay.